Patent · US Active

3-imidazolyl-indoles for the treatment of proliferative diseases

US8053457B2 · kind B2 · utility

2Cited by

1References

11Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Andreas Boettcher · Basel, CH
Nicole Buschmann · Basel, CH
Pascal Furet · Basel, CH
Jean-Marc Groell · Basel, CH
Jörg Kallen · Basel, CH
Joanna Hergovich Lisztwan · Basel, CH
Keiichi Masuya · Bottmingen, CH
Lorenz Mayr · Bingen, DE
Andrea Vaupel · Riehen, CH

Key dates

Filing date	Mar 27, 2008
Grant date	Nov 8, 2011
Priority date	—
Expiry date	Jul 11, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention relates to 3-heterocyclyl indolyl compounds of formula I capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively:whereinR1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.